Apollon Formularies Jamaica

Apollon Formularies Jamaica is a medical cannabis pharmaceutical company specializing in the development of cannabinoid-based formulations for the treatment of cancer and chronic pain. Based in Jamaica, the company leverages the country's legal framework to conduct clinical research and manufacture medical-grade cannabis products. Their portfolio includes proprietary formulations that have shown efficacy in treating various cancer cell lines in laboratory settings and observational clinical trials. In 2023, the company reached an agreement to sell its intellectual property and Jamaican assets to Global Cannabis Applications Corp. The company's approach combines traditional pharmaceutical rigor with the therapeutic potential of phytocannabinoids.